The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The Momentum Indicator moved above the 0 level on December 18, 2024. You may want to consider a long position or call options on OVATF as a result. In of 44 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for OVATF turned negative on December 04, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 50-day moving average for OVATF moved below the 200-day moving average on December 05, 2024. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Aroon Indicator for OVATF entered a downward trend on December 16, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.033) is normal, around the industry mean (57.958). P/E Ratio (0.000) is within average values for comparable stocks, (89.727). OVATF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.947). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (0.694) is also within normal values, averaging (19.472).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. OVATF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OVATF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Industry PharmaceuticalsOther
A.I.dvisor tells us that OVATF and KKPCF have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OVATF and KKPCF's prices will move in lockstep.
Ticker / NAME | Correlation To OVATF | 1D Price Change % | ||
---|---|---|---|---|
OVATF | 100% | N/A | ||
KKPCF - OVATF | 24% Poorly correlated | N/A | ||
KHTRF - OVATF | 24% Poorly correlated | N/A | ||
NPPNY - OVATF | 10% Poorly correlated | N/A | ||
RGEDF - OVATF | 6% Poorly correlated | N/A | ||
PCLOF - OVATF | 4% Poorly correlated | -10.64% | ||
More |
Ticker / NAME | Correlation To OVATF | 1D Price Change % |
---|---|---|
OVATF | 100% | N/A |
Pharmaceuticals category (308 stocks) | 4% Poorly correlated | -1.36% |
Pharmaceuticals: Other category (226 stocks) | -3% Poorly correlated | -1.31% |